


OBJECTIVES



→ To compare the prescribed dose of Dimethylfumarate (DMF) to the recommended one.

→ To evaluate tolerability of this treatment.

Recommended dose of DMF



METHODS

✓ Study : May to July 2014 = 3 months.

✓ Every new patient with a prescription of DMF was included.

✓ Several data collected :

- Information about patient (age ...)
- Medical history of patients (treatment before DMF, reason of DMF prescription...)
- Dosage regimen of DMF for each patient
- Adverse events (patients were questioned when they came at pharmacy to get their treatment)

RESULTS

Data about patients

→ 30 patients included


♀ 24
♂ 6

→ Mean age : 46 [26 ; 64]


→ Mean age when multiple sclerosis was diagnosed : 32 years

Treatment history with Dimethylfumarate

First prescription of DMF




Reasons for prescribing DMF




Dosage regimen and tolerability

Starting dose of DMF



Side effects



There were side effects for :

- 63% of patients receiving the recommended starting dose
- 85% of the others

After 1 month, no more adverse events for 95% of patients.



4 patients have discontinued treatment with DMF due to multiple sclerosis relapse.

DISCUSSION / CONCLUSION

This study shows that prescribers have followed the recommended starting dose for only 53% of patients.

A more gradual dosing regimen for the starting dose doesn't seem to reduce occurrence of side effects.

It will be interesting to confirm this result by studying frequency of occurrence of adverse events and using scales to assess quality of life compare to injectable therapies.